Cyclerion Therapeutics (NASDAQ:CYCN) Issues Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) posted its earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($7.10) by $6.69, FiscalAI reports. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%.

Cyclerion Therapeutics Price Performance

Shares of CYCN stock traded up $0.05 during trading hours on Thursday, hitting $3.60. The stock had a trading volume of 746 shares, compared to its average volume of 2,555,990. The stock’s 50-day moving average price is $3.38 and its two-hundred day moving average price is $2.63. Cyclerion Therapeutics has a one year low of $1.03 and a one year high of $8.48. The stock has a market capitalization of $16.85 million, a price-to-earnings ratio of -2.65 and a beta of 1.76.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.